These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 22641598

  • 1. Cutaneous leishmaniasis in a patient with ankylosing spondylitis using adalimumab.
    Gomes KW, Benevides AN, Vieira FJ, Burlamaqui MP, Vieira Mde A, Fontenelle LM.
    Rev Bras Reumatol; 2012; 52(3):447-52. PubMed ID: 22641598
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dosage adjustment of anti-tumor necrosis factor-α inhibitor in ankylosing spondylitis is effective in maintaining remission in clinical practice.
    Paccou J, Baclé-Boutry MA, Solau-Gervais E, Bele-Philippe P, Flipo RM.
    J Rheumatol; 2012 Jul; 39(7):1418-23. PubMed ID: 22707611
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Occurrence of vitiligo in a patient with ankylosing spondylitis receiving adalimumab].
    Toussirot E, Salard D, Algros MP, Aubin F.
    Ann Dermatol Venereol; 2013 Dec; 140(12):801-2. PubMed ID: 24315228
    [No Abstract] [Full Text] [Related]

  • 8. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
    Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J.
    Arthritis Rheum; 2007 May 15; 57(4):639-47. PubMed ID: 17471540
    [Abstract] [Full Text] [Related]

  • 9. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD.
    Ann Rheum Dis; 2008 May 15; 67(5):710-2. PubMed ID: 18079191
    [Abstract] [Full Text] [Related]

  • 10. Drug insight: anti-tumor-necrosis-factor therapy for ankylosing spondylitis.
    Henderson C, Davis JC.
    Nat Clin Pract Rheumatol; 2006 Apr 15; 2(4):211-8. PubMed ID: 16932687
    [Abstract] [Full Text] [Related]

  • 11. Splenic tuberculosis in a patient with ankylosing spondylitis treated with adalimumab.
    Azevedo VF, Paiva E, Tosin T, Ferreira A, Ferreira AM, Fernandes M.
    Reumatismo; 2011 Nov 09; 63(3):171-4. PubMed ID: 22257918
    [Abstract] [Full Text] [Related]

  • 12. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation.
    de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, Nurmohamed MT, Dijkmans BA, Aarden LA, Wolbink GJ.
    Ann Rheum Dis; 2009 Nov 09; 68(11):1787-8. PubMed ID: 19822712
    [No Abstract] [Full Text] [Related]

  • 13. The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.
    Nell-Duxneuner V, Schroeder Y, Reichardt B, Bucsics A.
    Int J Clin Pharmacol Ther; 2012 Dec 09; 50(12):867-72. PubMed ID: 23036238
    [Abstract] [Full Text] [Related]

  • 14. [Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept].
    Breedveld FC.
    Ned Tijdschr Geneeskd; 2005 Oct 08; 149(41):2273-7. PubMed ID: 16240851
    [Abstract] [Full Text] [Related]

  • 15. Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists.
    Lee HH, Song IH, Friedrich M, Gauliard A, Detert J, Röwert J, Audring H, Kary S, Burmester GR, Sterry W, Worm M.
    Br J Dermatol; 2007 Mar 08; 156(3):486-91. PubMed ID: 17300238
    [Abstract] [Full Text] [Related]

  • 16. BAFF levels in patients with ankylosing spondylitis and response to anti-tumor necrosis factor treatment.
    Niederer F, Scherer A, Kyburz D, Gay RE, Gay S, Michel BA, Ciurea A.
    Joint Bone Spine; 2013 Jul 08; 80(4):433-4. PubMed ID: 23165181
    [No Abstract] [Full Text] [Related]

  • 17. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
    Barra L, Pope JE, Payne M.
    J Rheumatol; 2009 Jul 08; 36(7):1421-8. PubMed ID: 19487267
    [Abstract] [Full Text] [Related]

  • 18. Multiple paradoxical adverse events in a patient affected with ankylosing spondylitis treated with TNF blockers.
    Lo Nigro A, Ramonda R, Alaibac M, Modesti V, Punzi L.
    Eur J Dermatol; 2011 Jul 08; 21(2):263-4. PubMed ID: 21411412
    [No Abstract] [Full Text] [Related]

  • 19. No significant changes in arterial stiffness in patients with ankylosing spondylitis after tumour necrosis factor alpha blockade treatment for 6 and 12 months.
    Mathieu S, Pereira B, Couderc M, Rabois E, Dubost JJ, Soubrier M.
    Rheumatology (Oxford); 2013 Jan 08; 52(1):204-9. PubMed ID: 23065359
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.